Deciphera Pharmaceuticals (NASDAQ: DCPH)
Some price data may be temporarily unavailable.
Deciphera Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Deciphera Pharmaceuticals Company Info
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
News & Analysis
3 Under-the-Radar Biotech Stocks to Buy in 2023
All three biotech companies focus on oncology therapies.
Why Shares of Deciphera Pharmaceuticals Rose This Week
The company's shares rose after the company reported second-quarter earnings.
Why Deciphera Pharmaceuticals Stock Jumped This Week
The company's lead therapy received an FDA Breakthrough Therapy designation.
Why Deciphera Pharmaceuticals Shot 12% Higher Today
The company announced a comprehensive restructuring program.
3 Biotech Stocks With Huge Catalysts Incoming
These drugmakers have big events that should occur before the end of 2021.
2 Beaten-Down Biotech Stocks That Could Bounce Back
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
3 Biotech Stocks That Could Double Soon
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?
The company isn't earning a profit yet, but there are solid reasons why it worth considering, particularly at its current share price.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.